Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.
Novartis won the go-ahead from the U.S. Food and Drug Administration to conduct a randomized trial of the malaria drug hydroxychloroquine against COVID-19 disease to see if the medicine helps patients.
Roche Holding AG Chief Executive Officer Severin Schwan said in an interview with CNBC it could take at least a couple of weeks, if not months, for the United States to implement broad testing for coronavirus.
A new campaign from Horizon Therapeutics called Down and Out Kidney sheds light on the prevalence and impact of gout in chronic kidney disease, and aims to facilitate an important conversation with nephrologists – kidney specialists – particularly during National Kidney Month (March).
Novartis boss Vas Narasimhan expects higher sales and profitability for 2020, lifted by the company’s broad range of medicines, and minimal disruption to the Swiss drugmaker’s supply chain from the coronavirus outbreak in China.
Gilead Sciences and Eisai entered into an agreement for the distribution and co-promotion of the investigational, oral, selective JAK1 inhibitor filgotinib in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA).
Gilead Sciences Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the investigational, oral, selective JAK1 inhibitor filgotinib for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
Pfizer Inc.’s rheumatoid arthritis drug Xeljanz could increase the risk of blood clots in the lungs and in deep veins, the European Medicines Agency (EMA) said.
